Trial Profile
Women's Triple-Negative First-Line Study: A Phase II Trial of Liposomal Doxorubicin, Bevacizumab and Everolimus (DAE) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Doxorubicin liposomal (Primary) ; Everolimus (Primary)
- Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 25 May 2023 Status changed from active, no longer recruiting to completed.
- 22 Feb 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 22 Feb 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.